xeplion 100 mg suspensie injectabilă cu eliberare prelungită
janssen-cilag international nv - paliperidonum - suspensie injectabilă cu eliberare prelungită - 100 mg
xeplion 150 mg suspensie injectabilă cu eliberare prelungită
janssen-cilag international nv - paliperidonum - suspensie injectabilă cu eliberare prelungită - 150 mg
xeplion 50 mg suspensie injectabilă cu eliberare prelungită
janssen-cilag international nv - paliperidonum - suspensie injectabilă cu eliberare prelungită - 50 mg
xeplion 75 mg suspensie injectabilă cu eliberare prelungită
janssen-cilag international nv - paliperidonum - suspensie injectabilă cu eliberare prelungită - 75 mg
zytiga comprimate 250 mg
janssen-cilag international nv - abirateronum - comprimate - 250 mg
avamys spray nazal, suspensie 27,5 mcg/doza
glaxo operation uk limited - spray nazal, suspensie - 27,5 mcg/doza
avamys spray nazal, suspensie 27,5 mcg/doza
glaxo operation uk limited - spray nazal, suspensie - 27,5 mcg/doza
betaferon 250 mcg/ml pulbere şi solvent pentru soluţie injectabilă
bayer pharma ag - interferonum beta 1b - pulbere şi solvent pentru soluţie injectabilă - 250 mcg/ml
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agenți antineoplazici - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.
adempas
bayer ag - riociguat - hipertensiune arterială, pulmonară - antihipertensive pentru hipertensiunea arterială pulmonară - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. eficacitatea a fost demonstrată într-un hap populației, inclusiv etiologii ale idiopatică sau ereditară pah sau htap asociată bolilor de țesut conjunctiv. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.